Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVOLOCUMAB and Coronary Microvascular Dysfunction in Coronary Angiography Patients
2024-519012-14-00Phase 2Authorised
- Sponsor
- CHU Grenoble Alpes
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of evolocumab in atherosclerotic disease and Coronary Small Vessel Disease (CMD) (2 arms), sponsored by CHU Grenoble Alpes. Primary endpoint: Index of microcirculatory resistance (IMR). Planned start Nov 2024; status: authorised.
02
Drugs
evolocumab
03
Conditions
atherosclerotic diseaseCoronary Small Vessel Disease (CMD)
Beyond the preview
Go deeper on 2024-519012-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519012-14-00.